Marchand v. Barnhill — The Oversight Duty, Seen from Switzerland

On 18 June 2019, Chief Justice Strine, writing for a unanimous Delaware Supreme Court, reversed the Court of Chancery’s dismissal of a derivative claim against the directors of Blue Bell Creameries USA. Three people had died in a 2015 listeria outbreak traced to the company’s ice cream. Blue Bell’s board had no committee addressing food safety, received no board-level reports on food safety, and took no independent steps to assure itself that the company’s single product line was being produced safely. The decision, Marchand v. Barnhill, is the most important oversight-liability decision from Delaware in twenty years. It matters to Swiss boards because the substantive duty it articulates — that directors must implement and monitor a board-level information system for mission-critical risks — is already part of Swiss law, through Art. 716a(1)(5) OR, and is easier to plead against Swiss directors than against Delaware ones.

The Caremark lineage

Delaware oversight liability begins with In re Caremark International Inc. Derivative Litigation, 698 A.2d 959 (Del. Ch. 1996). Chancellor Allen held that directors have an affirmative duty to assure themselves that information and reporting systems reasonably designed to provide timely, accurate information exist within the corporation. Liability under the standard was deliberately narrow: a "sustained or systematic failure of the board to exercise oversight," in Allen’s formulation — a “demanding test” he himself described as “possibly the most difficult theory in corporation law upon which a plaintiff might hope to win a judgment.”

Ten years later, in Stone v. Ritter, 911 A.2d 362 (Del. 2006), the Delaware Supreme Court reformulated Caremark as a duty-of-loyalty doctrine. Liability now required bad faith: either that the directors "utterly failed to implement any reporting or information system or controls," or that, having implemented such a system, they “consciously failed to monitor or oversee its operations.” The pleading burden became correspondingly formidable. For a decade and a half after Stone, Caremark claims were pled often and sustained almost never.

Marchand changed that. It did not re-engineer the doctrine, but it held directors accountable on facts where the bad-faith gloss would otherwise have been a shelter. The direction since — through In re Clovis Oncology (2019), Hughes v. Hu (2020), Teamsters Local 443 v. Chou (2020) on AmerisourceBergen’s opioid diversion, In re The Boeing Co. Derivative Litigation (2021), and City of Detroit Police & Fire Retirement System v. Hamrock (2024) on the Columbia Gas / Merrimack Valley explosions — is unmistakable: Caremark is no longer theoretical. Where the risk is central to the business and the board has no visible system addressing it, Delaware courts are willing to let derivative cases proceed past a motion to dismiss.

The facts and the holding in Marchand

Blue Bell Creameries was, as Strine observed, a “monoline” company: it made ice cream, and that was substantially all it made. A listeria outbreak in early 2015 caused three deaths, a company-wide recall, the layoff of a third of the workforce, and the near-collapse of the firm. The board of directors — which had received presentations on finance, marketing, and distribution — had not in any identifiable way received board- level information on food safety. There was no board committee charged with it. Management-level compliance existed, but the board had neither erected nor monitored an oversight system of its own.

The Supreme Court held the complaint adequately alleged a Caremark breach. Its reasoning is crisp. Where a corporation’s core operational activity is exposed to a risk whose realisation would be catastrophic — here, food safety in a single-product food company — the directors' duty of loyalty requires them to implement a board-level monitoring system. It is not sufficient that management has compliance processes of its own. It is not sufficient that no legal breach has yet been identified. The board must affirmatively build, and then actually use, its own reporting and information channel for the mission-critical risk. Absence of such a channel — total absence — is the breach.

Marchand's innovation is not new doctrine. It is the identification of a sub-category — mission-critical risk — in which the expected board response is elevated and the pleading threshold correspondingly lowered. Post-Marchand derivative complaints have routinely framed the plaintiff’s case around what the mission-critical risk was, whether a board-level system existed to address it, and what board minutes recorded about it.

How a Swiss court would decide the same facts

A Swiss court reading the Blue Bell record would reach the same conclusion, and would reach it through doctrine that is, on several axes, sterner than Caremark.

The statutory anchor is Art. 716a OR, which catalogues the board’s non-delegable and non-transferable duties. Among them, at paragraph 1 item 5, is die Oberaufsicht über die mit der Geschäftsführung betrauten Personen, namentlich im Hinblick auf die Befolgung der Gesetze, Statuten, Reglemente und Weisungen — the high-level oversight of those entrusted with management, particularly with respect to compliance with laws, articles, regulations, and instructions. The duty is not assigned to a committee. It is not delegable downward. It sits on every member of the board.

Art. 717 OR then supplies the performance standard: the duty of care of an ordentlicher und gewissenhafter Geschäftsleiter, an orderly and conscientious manager. Swiss doctrine measures this standard objectively. There is no counterpart to Delaware’s Stone v. Ritter bad-faith requirement: a director who failed to meet the objective standard breaches the duty whether or not the failure was conscious and whether or not it was loyalty-tainted. The standard adjusts to the risk profile — a principle rehearsed in BGE 113 II 52 and refined in later decisions — so a company whose dominant operational risk is food safety is expected to produce a board-level oversight response proportionate to that risk.

Enforcement runs through Art. 754 OR: directors are personally liable for damage caused to the company, to shareholders, and — in bankruptcy — to creditors. Where the company is insolvent, claims typically pass to individual creditors by cession under Art. 260 SchKG, which in Swiss practice is the most common vehicle for oversight-type liability actions. This is the same enforcement architecture at work in the Papierschlamm case — 4A_62/2024 — where a Swiss board’s failure to form reserves for a foreseeable environmental liability produced joint and several personal liability.

Three consequences follow on Blue Bell-type facts. First, under Swiss law the duty to have a board-level monitoring system for mission-critical risks is not an innovation that requires the identification of a sub-category; it is the baseline meaning of Oberaufsicht in Art. 716a(1)(5) OR applied to a risk warranting it. Second, the claim against Swiss directors does not need to satisfy a bad-faith standard — a failure to meet the objective care standard suffices under Art. 717 OR. Third, the Swiss faktisches Organ doctrine — as Papierschlamm confirms — captures non-formal directors who substantively participate in oversight-bearing functions (external auditors with joint signatory authority, counsel with significant managerial intervention, trustees exercising influence). Delaware oversight liability reaches only record directors.

Where the two systems converge, and where they do not

Convergence. Both jurisdictions now hold that directors must establish, and not merely acquiesce in, a reporting system that makes them aware of risks to the business. Both reject the position that management-level compliance suffices. Both treat the absence of any board-level information channel on a central risk as the clearest evidence of breach. Both contemplate that board minutes, committee charters, and the documented flow of compliance information to the board are what a court will look at first.

Divergence. Delaware requires a pleading of bad faith — of conscious disregard or utter failure; Swiss law requires only a breach of the objective care standard. Delaware liability runs against record directors; Swiss liability additionally reaches faktisches Organe. Delaware’s doctrine elevates its demands on boards for a specific sub-category — mission-critical risks; Swiss doctrine applies one uniform care standard to all boards, calibrated in intensity to the risk profile of the business, and supplements it with sectoral overlays (banking under BankG/FINMAG, pharmaceuticals under HMG, insurance under VAG, and so on) that perform a function analogous to Marchand's mission-critical category. The procedural posture also differs: Delaware derivative actions must clear demand-futility pleading under the Zuckerberg framework; Swiss actions are brought either by the company itself, by qualifying shareholders, or — most often in practice — by creditors by cession under Art. 260 SchKG after bankruptcy.

What boards should take from it

1. Mission-critical oversight is already required under Swiss law. A Swiss board that cannot evidence a documented, board-level flow of information on its central operational risks — product safety in a food business, patient safety in a pharma or medtech business, model risk in a quantitative asset manager, AML in a bank, cyber in a data-handling business — is exposed under Art. 716a(1)(5) and Art. 717 OR. The exposure does not await a bad-faith showing.

2. Charters, minutes, and KPIs do the evidentiary work. In Delaware, Marchand-style pleading lives or dies on whether board minutes record substantive engagement with the mission-critical risk. In Swiss practice, the evidentiary map is the same: charters defining committee oversight of the specific risk; minutes reflecting board-level engagement with the relevant KPIs; a discoverable flow of reports from management to the board. A Swiss board that cannot produce these is disarmed when litigation readiness comes to matter.

3. For Swiss-listed groups with Delaware subsidiaries, Marchand now applies to the sub-board. Where a Delaware-incorporated operating subsidiary is the locus of mission-critical operational risk, its directors — even if Swiss residents — are measured against the post-Marchand standard. A Swiss parent board that treats the sub-board as purely internal reporting apparatus misreads the risk. Conversely, a Swiss-incorporated parent overseeing Delaware operations must be conscious that its own Art. 716a oversight duty interlocks with, but does not dissolve into, the sub-board’s Caremark exposure.

4. Sectoral regulators are the functional Swiss analogue to “mission-critical.” A Swiss bank board owes FINMA expectations that functionally describe a mission-critical reporting regime for prudential and conduct risk. A Swiss pharma board owes Swissmedic expectations that functionally describe a mission-critical reporting regime for pharmacovigilance. The regulator is doing, in effect, the work that Marchand does in Delaware when no regulator is speaking loudly. Non-regulated Swiss boards — in food, in consumer products, in technology — have neither a regulator nor Marchand and should be correspondingly attentive to their own oversight architecture; the exposure is the same, the external scaffolding is thinner.

Implications for the reference work

Director Duties under Swiss Law, at the oversight section, will be updated to incorporate the mission-critical framing as a Swiss-law application of Art. 716a(1)(5) OR, cross-referenced to Marchand. Corporate Criminal Exposure will note that oversight failures of the Marchand type are frequently the predicate for Art. 102 StGB corporate liability — the civil and criminal exposures track each other on the same factual pattern. Board Duties in the Governance of AI Systems will adopt the mission-critical framing directly: for boards whose business is materially intermediated by AI, model risk and autonomous-action risk are the Marchand subject of the decade.

Primary sources

Delaware decisions: Marchand v. Barnhill, 212 A.3d 805 (Del. 2019) (Chief Justice Strine for a unanimous court); In re Caremark International Inc. Derivative Litigation, 698 A.2d 959 (Del. Ch. 1996) (Chancellor Allen); Stone v. Ritter, 911 A.2d 362 (Del. 2006); and the post-Marchand lineage including Clovis Oncology, Hughes v. Hu, Teamsters Local 443 v. Chou (AmerisourceBergen), In re Boeing, and the Columbia Gas / Merrimack Valley cases.

Swiss sources cited: Art. 716a OR (non-delegable board duties; oversight at paragraph 1 item 5), Art. 717 OR (duty of care, objective standard), Art. 754 OR (liability), Art. 260 SchKG (cession of claims to creditors in bankruptcy), BGE 113 II 52, BGE 139 III 24, BGE 140 III 533 (Cash-Pool-Entscheid). Sectoral overlays: BankG, FINMAG, HMG, VAG. Case cross-references are to opencaselaw.ch where the decisions are Swiss.

See also

• Director Duties under Swiss Law
• Corporate Criminal Exposure
• Board Duties in the Governance of AI Systems
• Commentary: 4A_62/2024 — the Papierschlamm case
• Commentary: BTI v Sequana — the creditor duty, seen from Switzerland
• Glossary: Verantwortlichkeitsklage
• Glossary: Faktisches Organ